Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1388320/000121390021026493/f10q0321_actiniumpharma.htm
SEC Filings
ATNM Annual Reports
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report May 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report March 2015
10-K Annual Report February 2014
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report May 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report March 2015
10-K Annual Report February 2014
ATNM Quarterly Reports
ATNM Corporate News
Regulated Disclosure March 2023
Financial Exhibit
Regulated Disclosure February 2023
Event for Officers
Financial Exhibit
Vote of Security Holders December 2022
Other Events December 2022
Financial Exhibit
Regulated Disclosure October 2022
Financial Exhibit
New Agreement June 2022
New Agreement April 2022
Event for Officers
Financial Exhibit
Vote of Security Holders November 2021
Event for Officers
Financial Exhibit
Regulated Disclosure September 2021
Event for Officers
Financial Exhibit
Vote of Security Holders November 2020
Regulated Disclosure
March 2023
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
February 2023
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
December 2022
Other Events
December 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
October 2022
Financial Exhibit
New Agreement
New Agreement
June 2022
New Agreement
April 2022
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
November 2021
Event for Officers
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
September 2021
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
November 2020
Last10K.com | 10-Q Quarterly Report Fri May 14 2021
Document And Entity Information - shares | 3 Months Ended | |
|---|---|---|
Mar. 31, 2021 | May 14, 2021 | |
| Document Information Line Items | ||
| Entity Registrant Name | Actinium Pharmaceuticals, Inc. | |
| Document Type | 10-Q | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Common Stock, Shares Outstanding | 20,194,869 | |
| Amendment Flag | false | |
| Entity Central Index Key | 0001388320 | |
| Entity Current Reporting Status | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Document Period End Date | Mar. 31, 2021 | |
| Document Fiscal Year Focus | 2021 | |
| Document Fiscal Period Focus | Q1 | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity File Number | 001-36374 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Interactive Data Current | Yes |
View differences made from one quarter to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Actinium Pharmaceuticals, Inc..
Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Cash Flow Highlight
The following tables sets forth selected cash flow information for the periods indicated: Net cash used in operating activities for the three months ended March 31, 2021 of $5.6 million decreased by $0.3 million from $5.9 million in the prior-year period, primarily due to the earned revenue.
-
Other - Other Highlight
In determining whether goods or services are distinct, we evaluate certain criteria, including whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and (ii) the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the contract).
-
Other - Other Highlight
A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could in the future negatively affect our liquidity.
-
Other - Other Highlight
This ASU is effective January 1, 2022 and interim periods presented, although early adoption of this ASU was permitted effective January 1, 2021.
-
Revenue - Product Highlight
The consideration is recognized to revenue over each module and revenue recognized during the three months ended March 31, 2021 of $0.6 million was due to the recognition of revenue from nonrefundable payments received from the third-party.
-
Financial - Shares
Specifically, the ASU eliminated the...Read more
-
Revenue - Product
To determine revenue recognition for...Read more
-
Other - Other
We believe our ARC approach...Read more
-
Revenue - Geography
In the European Union ("EU"),...Read more
-
Other - Other
These factors include but are...Read more
-
Financial - Expense
General and administrative expenses of...Read more
-
Other - Other
Results with MSKCC's 19-28z CD-19...Read more
-
Other - Other
At contract inception, once the...Read more
-
Other - Other
These non-targeted conditioning regimens are...Read more
-
Other - Other
We have particular expertise in...Read more
-
Other - Other
These items are monitored and...Read more
-
Other - Other
We intend to develop our...Read more
-
Other - Other
Our CD33 development program is...Read more
-
Other - Other
Such government-imposed precautionary measures may...Read more
-
Other - Other
The effective life of the...Read more
-
Other - Other
Such events may result in...Read more
-
Revenue - Product
Overall, transplant procedures in the...Read more
-
Other - Other
I-131-Apamistamab has clinical proof of...Read more
-
Other - Other
Furthermore, in vivo studies in...Read more
-
Revenue - Product
The relative standalone selling price...Read more
-
Revenue - Geography
The control arm is also...Read more
-
Other - Other
The universal engraftment rate and...Read more
-
Financial - Expense
Research and development expenses increased...Read more
-
Other - Other
We believe our Iomab-ACT program...Read more
-
Other - Other
Unlike chemotherapy, Iomab-ACT is targeted...Read more
-
Other - Other
The amount for the three...Read more
-
Other - Other
We follow the accounting guidance...Read more
-
Other - Other
Further, the continuation and/or resurgence...Read more
-
Revenue - Product
Under ASC 606, we recognize...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Consolidated Balance Sheets (Unaudited)
Consolidated Balance Sheets (Unaudited) (Parentheticals)
Consolidated Statement Of Changes In Stockholders??? Equity (Unaudited)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Accounting Policies, By Policy (Policies)
Commitments And Contingencies
Commitments And Contingencies (Details)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Antidilutive Securities Excluded From Computation Of Diluted Net Loss Per Share
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Cash And Cash Equivalent And Restricted Cash
Description Of Business And Summary Of Significant Accounting Policies (Tables)
Equity
Equity (Details) - Schedule Of Stock Option Activity
Equity (Details) - Schedule Of Warrant Activities
Equity (Details)
Equity (Tables)
Leases
Leases (Details) - Schedule Of Components Of Lease Expense
Leases (Details) - Schedule Of Maturities Of Lease Liabilities
Leases (Details) - Schedule Of Supplemental Cash Flow Information Related To Leases
Leases (Details) - Schedule Of Weighted Average Discount Rates
Leases (Details) - Schedule Of Weighted Average Remaining Lease Terms
Leases (Tables)
Other Revenue
Other Revenue (Details)
Subsequent Event
Subsequent Event (Details)
Material Contracts, Statements, Certifications & more
Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ATNM
CIK: 1388320
Form Type: 10-Q Quarterly Report
Accession Number: 0001213900-21-026493
Submitted to the SEC: Fri May 14 2021 5:00:39 PM EST
Accepted by the SEC: Fri May 14 2021
Period: Wednesday, March 31, 2021
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/atnm/0001213900-21-026493.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...